Acute leukemia in adults: novel allogeneic transplant strategies

References

• Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, et al.. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007;13(11):1268–85.
   PubMed Web of Science ®Google Scholar
• Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, et al.. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood. 2010;115(4):757–65.
   PubMed Web of Science ®Google Scholar
• de Lima M, Robinson S, McMannis J, et al.. Mesenchymal stem cell (MSC) based cord blood (CB) expansion (Exp) leads to rapid engraftment of platelets and neutrophils (abstract #362). Blood. 2010;116:362.
   Web of Science ®Google Scholar
• de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, et al.. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008;41(9):771–8.
   PubMed Web of Science ®Google Scholar
• Delaney C, Ratajczak MZ, Laughlin MJ. Strategies to enhance umbilical cord blood stem cell engraftment in adult patients. Expert Rev Hematol. 2010;3(3):273–83.
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S57–63.
   PubMedGoogle Scholar
• Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al.. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–8.
   PubMed Web of Science ®Google Scholar
• Agura E, Berryman RB, Pineiro L, Vance E, Tadic-Ovcina M, Woelfel RG, et al.. Preliminary results of phase II trial of clofarabine with parenteral busulfan (CLO/BU) followed by allogeneic related or unrelated donor transplantation for the treatment of hematologic malignancies (abstract #399). Biol Blood Marrow Transplant. 2011;17:S298–9.
   Web of Science ®Google Scholar
• Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R, et al.. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant. 2012;18(3):432–40.
   Google Scholar
• Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplant. 2012;47(1):5–14.
   Google Scholar
• Michallet M, Sobh M, Morisset S, Tedone N, Bay JO, Harousseau JL, et al.. Phase II prospective multicenter study of treosulfan based reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for hematological malignancies from 10/10 HLA identical unrelated donor. Biol Blood Marrow Transplant. 2011;17(2 Suppl):S285.
   PubMed Web of Science ®Google Scholar
• Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, et al.. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(3):341–50.
   PubMed Web of Science ®Google Scholar
• Rosenthal J, Wong J, Stein A, Qian D, Hitt H, Naeem A, et al.. Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. Blood. 2011;117(1):309–15.
   PubMed Web of Science ®Google Scholar
• Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, et al.. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303. Biol Blood Marrow Transplant. 2011;17(9):1343–51.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al.. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061–70.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al.. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921–8.
   PubMed Web of Science ®Google Scholar
• Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O, et al.. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):805–12.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, et al.. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005;11(5):389–98.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al.. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363(9419):1439–41.
   PubMed Web of Science ®Google Scholar